Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
Yasir Y. Elamin, Jacqulyne Robichaux, Brett W. Carter, Mehmet Altan, Hai T. Tran, Don L. Gibbons, Simon Heeke, Frank V. Fossella, Vincent K. Lam, Xiuning Le, Marcelo V. Negrão, Monique B. Nilsson, Anisha B. Patel, R. S. K. Vijayan, Jason B. Cross, Jianjun Zhang, Lauren A. Byers, Charles Lu, Tina Cascone, Lei Feng, Rajyalakshmi Luthra, F. Anthony San Lucas, Geeta Mantha, Mark Routbort, George R. Blumenschein, Anne S. Tsao, John V. Heymach
Topics & Concepts
T790MExonPoint mutationMutantCancer researchMutationDrug resistanceLung cancerBiologynon-small cell lung cancer (NSCLC)MedicineCancerEpidermal growth factor receptorOncologyInternal medicineGeneGeneticsGefitinibA549 cellLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancerCancer Genomics and Diagnostics